Phase 1 N=14 The Safety and Immunogenicity of a Potential HIV Vaccine
HIV Infections
Primary: Number of Participants With Moderate or Greater Reactogenicity (i.e., Solicited Adverse Events) — 2; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) for Balovaptan — 94.2; 12.9 ng/mL
Phase 1 N=28 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
HIV Infections
Primary: Frequency of Grade 2 or Higher Adverse Events (AEs) — 3; 5 Participants — p=0.072
Phase 1 N=15 A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) for Balovaptan — 31.5; 125; 140 ng/mL
Phase 1 N=13 The Maraviroc Central Nervous System (CNS) Study
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
Phase 1 N=32 A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval
Dyslipidemias
Primary: Change From Baseline in Fridericia's Correction for QT Interval (QTcF) — -4.6; 11.5; -6.0; -6.1 msec
Phase 1 N=276 A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet
Healthy Volunteers
Primary: Study 1, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Base of TAK-438 (TAK-438F)…
Phase 1 N=12 A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects
Autoimmune Diseases
Primary: Number of Subjects With Adverse Events (AEs) and Serious AEs (SAEs): Part A — 3; 6; 4; 7 Participants
Phase 1 N=13 The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
HIV
Primary: The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day — 0.99 ratio
Phase 1 N=38 OTR Tablet 40 mg Fasted-state Bioequivalence Study
Chronic Pain
Primary: Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State — 60.98; 52.23 ng/mL
Phase 1 N=14 Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Glucose Transporter Type 1 Deficiency Syndrome · GLUT1 Deficiency Syndrome
Primary: Number of Participants With Reduction in Spike-wave Fraction of the EEG Recording Time — 13 Participants
Phase 1 N=24 OTR Tablet 10 mg Fasted-state Bioequivalence Study
Chronic Pain
Primary: Cmax of OTR Tablet 10 mg and OXYCONTIN Tablet 10 mg in a Fasted State — 11.617; 10.564 ng/ml
Phase 1 N=48 Staccato Loxapine Thorough QT/QTc Study
Thorough QT/QTc Study
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.418 mseconds
Phase 1 N=81 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Difference in the Change From Baseline in Fasting Blood Glucose Between KQ-791 and Placebo — -3.28; -3.93; 0.67; 3.17 mg/dL milligrams per deciliters
Phase 1 N=14 The Effect of OASIS Ultra on Critical Sized Wound Healing
Traumatic Wound · Infective Wound · Iatrogenic Critical Sized Wound Defects
Primary: Change in Wound Size From Baseline to Final Wound Evaluation up to 60 Days Later — -20.7; -13.9 cm^2